枯草杆菌二联活菌肠溶胶囊联合美沙拉嗪肠溶片对溃疡性结肠炎患者的临床研究

Clinical efficacy of Bacillus subtilis and Enterococcus faecium enteric- coated capsules combined with mesalazin enteric- coated tablets in the treatment of the patients with ulcerative colitis

目的观察枯草杆菌二联活菌肠溶胶囊联合美沙拉嗪肠溶片对溃疡性结肠炎患者的临床疗效。方法入选118例溃疡性结肠炎患者,分为试验组59例和对照组59例。对照组口服美沙拉嗪肠溶片,每次1 g,每日3次。试验组在对照组基础上口服枯草杆菌二联活菌肠溶胶囊,每次500 mg,每日3次。2组疗程均为1个月。比较2组治疗1个月后临床疗效,治疗前后细胞因子白细胞介素-8(IL-8)、肿瘤坏死因子-α(TNF-α)水平变化、超氧化物歧化酶(SOD)和丙二醛(MDA)水平变化及不良反应。结果试验组总有效率显著高于对照组(P<0.05)。2组治疗后白细胞介素-8和TNF-α水平均显著低于治疗前(P<0.05);试验组治疗后白细胞介素-8水平显著低于对照组(P<0.05)。2组治疗后SOD水平较治疗前增加(P<0.05),丙二醛较治疗前减少(P<0.05);试验组治疗后SOD水平高于对照组(P<0.05),丙二醛水平低于对照组(P<0.05)。2组患者治疗期间均未发生明显的不良反应。结论枯草杆菌二联活菌肠溶胶囊联合美沙拉嗪肠溶片对溃疡性结肠炎患者的临床疗效显著,可明显降低白细胞介素-8,TNF-α,丙二醛水平和提高SOD水平。

Objective To investigate the clinical efficacy of Bacillus subtilis and Enterococcus faecium enteric -coated capsules combined with mesalazin enteric - coated in treatment of the patients with ulcerative colitis. Methods A total of 118 cases of patients with ulcerative colitis were divided into trial group（ n = 59） and control group （n = 59）. The control group was treated with mesalazin enteric - coated 1 g, rid, and the trial group were treated with Bacillus subtilis and Enterococcu^faecium enteric - coated capsule 500 rag, rid. The treatment lasted fi）r one month. The changes of interleukin - 8 （ IL - 8 ） , tumor necrosis factor -α （ TNF -α ） , superoxide dismutase （ SOD ） , methane dicarboxylic aldehyde （ MDA ） levels before anti after treatment and the adverse drug reaction were com- pared before and after treatment. Results The total effective rate in trial group was significantly higher than that of control group （ P 〈 0.05 ）. After treatment, the IL - 8, TNF -α levels in both groups were signifi- candy lower than that of before treatment （P 〈 0.05 ） ; after treatment, IL-8 levels in trial group was significantly lower than that of control group （ P 〈 0. 05 ） ; the SOD levels in both groups increased significantly （ P 〈 0.05 ） and MDA decreased significantly （P 〈 0.05 ）, the SOD levels in trial group was significantly higher than that of control group （P 〈 0.05 ） and the MDA was significantly lower than that of control group （P 〈 0.05 ）. There were no significant adverse drug reactions during the treatment course. Conclusion Clinical efficacy of Bacillus subtilis and Enterococcus faecium enteric - coated cap- sules combined with mesalazin enteric - coated in treatment of the patients with ulcerative colitis was significant, which can significantly reduce the IL- 8, TNF-α, and MDA levels and improve the SOD level.